➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Boehringer Ingelheim
AstraZeneca
Dow
Express Scripts

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

METHOTREXATE LPF Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Methotrexate Lpf patents expire, and when can generic versions of Methotrexate Lpf launch?

Methotrexate Lpf is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in METHOTREXATE LPF is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Methotrexate Lpf

A generic version of METHOTREXATE LPF was approved as methotrexate sodium by WEST-WARD PHARMS INT on September 16th, 1986.

  Start Trial

Summary for METHOTREXATE LPF
Drug patent expirations by year for METHOTREXATE LPF
Recent Clinical Trials for METHOTREXATE LPF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 1
Edwin HorwitzPhase 1
Institut CuriePhase 1/Phase 2

See all METHOTREXATE LPF clinical trials

Pharmacology for METHOTREXATE LPF

US Patents and Regulatory Information for METHOTREXATE LPF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira METHOTREXATE LPF methotrexate sodium INJECTABLE;INJECTION 011719-007 Mar 31, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
Johnson and Johnson
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.